Related Experiment Video

Updated: Jul 13, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

[Effects of proteasome inhibitors on leukemias]

Shu-Qing Lü1, Jian-Min Yang, Jian-Min Wang

  • 1Department of Hematology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|August 22, 2007
PubMed

Insights

The proteasome regulates protein degradation; its dysfunction signals cancer. Proteasome inhibitors, like bortezomib, show promise in treating various blood cancers, including multiple myeloma and leukemias.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Context:

  • The proteasome is a crucial cellular machine for protein degradation.
  • Aberrant proteasome activity is linked to cancer development (tumorigenesis).
  • Proteasome inhibitors represent a therapeutic strategy against various malignancies.

Purpose:

  • To review the therapeutic potential of proteasome inhibitors in hematologic malignancies.
  • To highlight the efficacy of bortezomib, a leading proteasome inhibitor, in clinical settings.
  • To consolidate research findings on proteasome inhibitor effects across different leukemia types.

Summary:

  • Proteasome inhibitors demonstrate anti-cancer activity in diverse malignancies.
  • Bortezomib, the first approved proteasome inhibitor, has shown high response and remission rates in multiple myeloma.
  • This review examines the impact of proteasome inhibitors on various leukemias, including plasma cell leukemia, chronic lymphocytic leukemia, adult T-cell lymphoma/leukemia, chronic myeloid leukemia, and acute myeloid leukemia.

Impact:

  • Establishes proteasome inhibitors as a viable therapeutic class for hematologic cancers.
  • Provides a comprehensive overview of bortezomib's success and potential in treating blood-related malignancies.
  • Informs future research and clinical applications of proteasome inhibitors in leukemia treatment.

More Related Videos

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons09:27

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons

Published on: October 10, 2025

Related Concept Videos

The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...